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Abstract
Background:  Carcinosarcoma of the colon is a rare histopathological entity with uncertain
histogenesis, that shows both epithelial and mesenchymal malignant differentiation.
Carcinosarcoma rarely affects the gastrointestinal tract and only few cases are reported in the
colon. Herein we describe a carcinosarcoma of the ascending colon, with morphological,
ultrastructural and molecular analysis.
Case presentation: An 81-year-old man was hospitalised for asthenia, weight loss and iron-
deficiency anaemia. The patient underwent colonoscopy and adenocarcinoma was diagnosed by
endoscopic biopsy. A right hemicolectomy was performed and, during surgical operation, liver
metastases were detected. Histological examination of the surgical specimen revealed areas of both
carcinomatous and sarcomatous differentiation, completely separated by fibrous septae. The
sarcomatous component exhibited areas of smooth muscle and osteoblastic differentiation, with
focal osteoid material deposition. Molecular analysis conducted separately on the epithelial and
mesenchymal components revealed the same p53 gene mutation (R282W in exon 8) and identical
polymorphisms in p53 exon 4, in EGFR exons 20 and 21, and in c-kit exon 17. Microsatellite markers
analysis revealed a common loss of heterozygosis on 18q. Overall, the data are consistent with a
common origin of the two tumor components. The patient was treated with 8 cycles of oral
capecitabine (1250 mg/m2 twice a day for 14 days repeated every 28 days) and two years after
surgery is alive with liver metastases.
Conclusion: Carcinosarcoma of the colon is a rare tumour with both epithelial and sarcomatous
components. Molecular analysis of the current case suggests the histogenesis from a common cell
progenitor.
Background
Carcinosarcoma is a rare histopathological entity, exhibit-
ing both epithelial and mesenchymal malignant differen-
tiation, with uncertain histogenesis. Carcinosarcoma has
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been described in various organs, although head and
neck, and female urogenital system are the most frequent
sites of occurrence [1]. In the gastrointestinal tract, carci-
nosarcoma arises predominantly in the oesophagus, in
the stomach and in the biliary tract [2], whereas carcinosa-
rcoma of the large intestine has been reported only rarely.
This type of tumour generally displays an aggressive
behaviour and poor prognosis. Herein we present a case
of carcinosarcoma of the ascending colon.
Case presentation
Clinical features
An 81-year-old man with a past medical history of athero-
sclerotic heart disease, arterial hypertension, mitral insuf-
ficiency, bilateral carotid artery disease and early chronic
renal failure was hospitalised for asthenia and weight loss.
Laboratory investigation revealed iron-deficiency anae-
mia, with low haemoglobin (Hb) concentration (7.8 g/dl;
normal range: 13–17 g/dL), median cellular volume
(MCV) level (67.2 fl; normal range: 80–97 fl) and serum
ferritin concentration (3.3 ng/mL; normal range: 30–400
ng/dL). Serum levels of carcinoembryonic antigen (CEA),
carbohydrate antigen (CA) 19-9 and alphafoetoprotein
(AFP) were within normal limits. Stool guaiac was posi-
tive for occult blood. Colonoscopy demonstrated an exo-
phytic mass in the ascending colon and multiple
diverticula in the entire colon, especially in the sigmoid
region. Endoscopic biopsies were performed and at histo-
logical examination, adenocarcinoma was diagnosed.
Chest x-ray was negative for metastatic disease. A week
later a right hemicolectomy and regional lymph node dis-
section were performed. During surgery, liver metastases
were detected. Computer tomography (CT) scan carried
out after surgery identified 3 liver nodules in segment 4,
in segment 8 and in segment 5, measuring 15 cm, 10 cm
and 10 cm in their greatest dimension, respectively. The
patient was subsequently treated with capecitabine at
1250 mg/m2 orally twice a day for 14 days repeated every
28 days for 8 cycles. Capecitabine was chosen for adjuvant
therapy in this case since it has been reported to be as
effective as 5-fluorouracil but with milder side effects in
stage III colon cancer [3]. No specific chemotherapeutic
agents have been shown to be effective in carcinosarcoma
[4]. Two years after surgical treatment, the patient is alive
with liver metastases.
Pathological features
Methods
Representative sections of the tumour and all lymph
nodes isolated from the surrounding adipose tissue were
fixed in 10% buffered neutral formalin, embedded in par-
affin and routinely processed. From each block, 5 µm-
thick sections were cut and stained with haematoxylin
and eosin (H&E).
For immunohistochemical studies, the avidin-biotin per-
oxidase complex method was used with the following
antibodies: cytokeratin 20 (CK20), desmin, vimentin, S-
100, c-kit, CD34, sarcomeric actin, smooth muscle actin,
osteonectin. The antibodies used are detailed in Table 1.
For ultrastructural examination, small samples were
retrieved from paraffin-embedded material, deparaffin-
ised in xylene, rehydrated in ethanol, post-fixed in
osmium tetroxyde (OsO4), dehydrated and embedded in
epoxy resin. Ultrathin sections were counterstained in
uranile acetate and lead citrate and observed in a Jeol JEM
1010 (Tokyo, Japan) electron microscope operating at 80
kV.
For the molecular detection of somatic genetic alterations,
the p53 gene (exons 4 through 9), the c-kit gene (exons 9,
11, 13 and 17) and the EGFR gene (kinase domain, exons
18 through 21) were evaluated by denaturing high-per-
formance liquid chromatography (DHPLC) technique
(The WAVE™ Nucleic Acid Fragment Analysis System,
Transgenomic Inc., Nebraska, USA), followed by direct
sequencing when required. K-Ras  gene mutation status
was assessed by direct sequencing. Distinct formalin-fixed
paraffin-embedded material from both carcinomatous
and sarcomatous components of the tumour was isolated
by macrodissection. Genomic DNA was extracted by the
phenol-chloroform method. Fifty ng of DNA were used
for the specific amplification of all the exons listed above,
as previously described [5-7]. After the polymerization
reaction, all PCR (Polymerase Chain Reaction) products
were visualised on a 2% agarose gel; 10 µl of the PCR
product were denatured at 95°C and slowly cooled to
room temperature to ensure equimolar homo- and heter-
oduplexes formation prior being loaded for DHPLC anal-
ysis. The running methods used are listed in Table 2. All
samples that showed an elution profile different from a
wild type control underwent direct sequencing by BigDye®
Terminator v1.1 Cycle Sequencing Kit chemistry, purified
by DyeEx 2.0 Spin kit (Qiagen, Hilden, Germany) and
analysed by capillary electrophoresis on Abi Prism 310
(Applied Biosystem, Foster City, California, USA).
Table 1: List of antibodies used
Antiserum Source Dilution Clone
Citokeratin 20 Novocastra 40 Ks20.8
Desmin Dako 100 D33
Vimentin Dako 1000 V9
S100 Dako 10000 Polyclonal
c-kit, CD 117 Dako 200 Polyclonal
CD 34 Novocastra 200 QBEnd/10
Sarcomeric Actin Dako 200 Alpha-Sr-1
Smooth Muscle Actin Biogenex 1000 1A4
Osteonectin Biodesign 50000 N50BMC Cancer 2006, 6:185 http://www.biomedcentral.com/1471-2407/6/185
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Sequences obtained were aligned with normal sequences
and examined for detection of mutations. For allelic status
testing, 10 microsatellite markers on chromosomal arms
9p, 11p, 13q, 17q and 18q were investigated (Rb,
D9S171, D11S1336, D13S258, D13S317, D13S631,
D17S855, D18S35, D18S51 and D18S585). Specific PCRs
with fluorescent primers were conducted followed by loss
of heterozygosis (LOH) analysis with GeneScan software
(Applied Biosystem, Foster City, California, USA).
Results
The surgical specimen included a 4 cm long ileal segment,
a 13.5 cm long colonic segment, and the caecal appendix.
At the ileocaecal valve, on the colonic side, an exophytic,
centrally ulcerated mass, measuring 7 cm in its greatest
dimension, was documented. Twenty-two lymph nodes
were isolated from the adipose tissue surrounding the
bowel wall.
Microscopically, about 70% of the tumour displayed fea-
tures of moderately differentiated adenocarcinoma,
invading the subserosa (pT3). The carcinoma was com-
posed of neoplastic epithelial cells, arranged in nests
forming glandular structures with areas of central necro-
sis. Neoplastic epithelial cells exhibited rare mitotic fig-
ures, an increased nuclear/cytoplasmic ratio and
prominent nucleoli. Approximately 30% of the tumour
presented mesenchymal features. The sarcomatous com-
ponent was completely separated from its carcinomatous
counterpart by fibrous septae (Fig. 1). In the sarcomatous
component, fascicular spindle cells admixed with bizarre
large cells and focal osteoid-like matrix deposition were
found. Fascicular spindle cells showed a moderately eosi-
nophilic cytoplasm, with slightly enlarged nuclei. Large
cells were markedly pleomorphic and exhibited enor-
mously swollen nuclei with irregularly dispersed chroma-
tin, focally surrounding areas of osteoid material
deposition in the extracellular matrix. Metastasis of aden-
ocarcinoma (N1) was found in 1 out of 22 lymph nodes
detected. According to the TNM classification [8], the
pathological stage was pT3N1.
The epithelial component was immunoreactive for CK20
in approximately 30% of neoplastic cells, whereas it was
negative for vimentin and osteonectin. In the mesenchy-
mal component, spindle cells were diffusely immunoreac-
tive for smooth muscle actin (Fig. 2) and partially positive
for vimentin, while large cells were focally immunoreac-
Tumour appearance on H&E Figure 1
Tumour appearance on H&E. Carcinomatous compo-
nent (left) and sarcomatous component (right) are com-
pletely separated by fibrous septae.
Table 2: Running methods and temperature used for DHPLC mutation detection
Gene-Exon (bp) Starting Gradient (%B) Temperature (°C)
p53-4 58.2 60.9/62.5
p53-5I 50 64.4
p53-5II 52.9 65.1
p53-6 53.1 61.5
p53-7 53.5 61.7/63.4/64.3
p53-8 54.6 59.8/62.8
p53-9 50.5 58.6/59.6
c-kit-9 56.5 55.3/58.5/59.5
c-kit-11 51.2 57.7/58.7
c-kit-13 55.4 56.7/58.7/59.3
c-kit-17 54.2 56.5/58
EGFR-18 (400) 57 60.9/62.9
EGFR-19 (372) 56.5 60.1
EGFR-20 (409) 57.2 61.2/63.4
EGFR-21 (415) 57.3 60.8BMC Cancer 2006, 6:185 http://www.biomedcentral.com/1471-2407/6/185
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tive for osteonectin (Fig. 3). Both the epithelial compo-
nent and the mesenchymal component were negative for
S100, desmin, CD34, c-kit and sarcomeric actin.
Ultrastructural examination was performed on both epi-
thelial and mesenchymal areas of differentiation. Epithe-
lial cells were organised in glandular structures encircled
by basal membrane and showed typical surface microvilla
and basal hemidesmosomes (Fig. 4A). Spindle cells exhib-
ited myofibroblastic differentiation with peripheral cyto-
plasmic thin filaments and interspersed focal densities
(Fig. 4B). There was no admixture of the two components.
The molecular screening performed to detect mutations
revealed in both tumour components the same mutation
R282W in exon 8 of the p53 gene (Figs. 5A, 5B). No muta-
tion was found in the k-ras gene. Although no mutations
could be detected, identical polymorphisms were identi-
fied in the carcinomatous as well as in the sarcomatous
components in p53 exon 4, in EGFR exons 20 and 21, and
in  c-kit  exon 17. The microsatellite analysis evidenced
shared allelic retentions and loss among the epithelial and
the mesenchymal neoplastic counteparts. Of the 10 STRs
(Short Tandem Repeats) investigated, 7 were considered
informative and four of them displayed an identical pat-
tern comparing normal and the two tumoral components.
An almost complete loss of the second allele was appreci-
ated for D18S585, D18S35 and D18S51 markers (18q21)
in both tumor' parts (Fig. 6).
Discussion
Carcinosarcoma is widely considered a rare, highly aggres-
sive tumour. Carcinosarcoma of the colon was first
reported by Weidner et al in 1986 [9] and to the best of
our knowledge, cases of colon carcinosarcomas and sarco-
matoid carcinomas reported in literature are 17 [4,9][10-
12][13-15][16-18][19-21][22-24], summarised in Table
3. Affected patients show an age between 41 and 84 years,
with a median age of 66 years and a slight predilection for
women. Lymph nodes and distant sites metastases dis-
close a predominance of the carcinomatous component.
Shah et al reported even an increased epithelial compo-
nent in the spleen metastasis, comparing with the primary
colon site [19]. Only one case with a metastasis from the
sarcomatous component was documented [18].
Herein we report a carcinosarcoma with distinct epithelial
and mesenchymal components, at the morphological,
immunohistochemical and ultrastructural levels. Moreo-
ver, the sarcomatous component was composed of cells
reminiscent of smooth muscle differentiation and cells
with osteoblastic appearance. Some authors classified as
large bowel carcinosarcomas epithelial tumours with
areas of sarcomatoid differentiation, weakly immunoreac-
tive for cytokeratins and with no evidence of osteosarco-
matous nor chondrosarcomatous differentation
[12,13,20,21]. According to Aramendi et al., these cases
are not properly carcinosarcomas, but should be consid-
ered sarcomatoid poorly differentiated carcinomas [23].
In the present case, the sarcomatous component com-
pletely lacked any epithelial signs of differentiation; fur-
thermore, we noted areas of osteosarcomatous
differentiation and osteoid material deposition. The top-
Immunohistochemical analysis on the sarcomatous compo- nent (smooth muscle actin) Figure 2
Immunohistochemical analysis on the sarcomatous 
component (smooth muscle actin). Fascicular spindle 
cells of the sarcomatous component are immunoreactive for 
smooth muscle actin in their cytoplasm. Internal control is 
positive, as shown by blood vessels staining.
Immunohistochemical analysis on the sarcomatous compo- nent (osteonectin) Figure 3
Immunohistochemical analysis on the sarcomatous 
component (osteonectin). Bizarre large cells of the sar-
comatous component are immunoreactive for osteonectin in 
their cytoplasm.BMC Cancer 2006, 6:185 http://www.biomedcentral.com/1471-2407/6/185
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ographic distribution was remarkable for the complete
separation of the two components. Ultrastructural exami-
nation confirmed such distinct separation. Bertram et al.
instead reported intermixed epithelial and mesenchymal
components [14]. Other authors have classified as carci-
nosarcomas or sarcomatoid carcinomas tumours with sar-
comatous features immunoreactive for cytokeratin and
epithelial membrane antigen (EMA), but lacking carcino-
matous component [4,15,16]. Shoji highlights the diffi-
culty in making the correct diagnosis, since sarcomatous
component closely resembles sarcoma, except for cytoker-
atin-immunoreactivity [16].
Treatment, as underlined by Bertram et al., should follow
guidelines for common colon adenocarcinomas [14] and
the poor prognosis associated with this tumour should
require a strict follow-up. Remarkably, the patient
reported here is still alive, two years after surgical resection
of the primary tumour, despite the presence of liver
metastases. Therefore we believe that aggressive therapy
may be indicated in these tumours.
The histogenesis of carcinosarcoma is still controversial.
Morphologically, the presence of distinct carcinomatous
and sarcomatous components suggests a different origin
(multiclonal hypothesis). The molecular analysis per-
formed in the current case supports the hypothesis of a
common cell precursor (monoclonal hypothesis), since
the same mutation R282W in exon 8 of the p53 gene as
well as the same allelic status, with the loss of 18q21, were
identified in both carcinomatous and sarcomatous com-
ponents.
Studies conducted on carcinosarcomas of nasopharynx
[25], uterus [26,27] and breast [28], documented a large
overlap of cytogenetic and molecular alterations in the
two tumour components. Furthermore, Van Rees et al.
[29] described an uncommon case of adenosquamous
carcinoma raised in a Barrett esophagus where the two
malignant components showed loss of the same allele at
all informative chromosomal markers tested as well as the
same missense mutation in the p53 tumor-suppressor
gene. All these findings are consistent with our results sug-
Ultrastructural examination Figure 4
Ultrastructural examination: (a) Carcinomatous component: glandular epithelial structure with surface microvilla (arrow); 
in the inset: enlargement of the basement membrane (arrow) and hemidesmosomes (red arrows). (b) Sarcomatous compo-
nent: spindle cells with actin cytoplasmic thin filaments and focal densities (enlargement in the inset). Scale bar: 2µm.BMC Cancer 2006, 6:185 http://www.biomedcentral.com/1471-2407/6/185
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gesting the hypothesis of a common progenitor of both
epithelial and mesenchymal components. Therefore mor-
phological divergence, even at the extreme levels dis-
played by carcinosarcomas, necessarily appears late in
tumor progression, well after the initial hits that cause
cancer.
Conclusion
Herein we describe a case of carcinosarcoma of the colon,
with epithelial and mesenchymal components, com-
pletely different and separate at the morphological,
immunohistochemical and ultrastructural levels. Molecu-
lar analysis revealed the same mutation R282W in exon 8
of the p53 gene and identical LOH for D18S585, D18S35
and D18S51 in both carcinomatous and sarcomatous
components, supporting the hypothesis of a common cell
progenitor.
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STR analysis evidenced a loss of heterozygosity on 18q21 Figure 6
STR analysis evidenced a loss of heterozygosity on 
18q21. Analysis of a representative marker of 18q21 (micro-
satellite D18S858) is shown. The carcinomatous (A) and sar-
comatous (B) components shared an almost complete loss of 
the second allele (arrow) in comparison to the normal (C) 
counterpart.
DHPLC diagram and p53 sequencing analysis Figure 5
DHPLC diagram and p53 sequencing analysis. (a) 
DHPLC diagram. The carcinomatous component is repre-
sented in black while the sarcomatous component in red and 
the wild-type control sample in blue. The same genetic alter-
ation in both tumour components is illustrated by the pres-
ence of an extra peak in the neoplastic specimens in 
comparison with the normal control. (b) Sequencing analysis 
showing p53 exon 8 mutation R282W (arrow).BMC Cancer 2006, 6:185 http://www.biomedcentral.com/1471-2407/6/185
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